

USANA HEALTH SCIENCES INC  
Form 10-Q  
November 07, 2018  
[Table of Contents](#)

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 29, 2018

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: 001-35024

---

## USANA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

**Utah**  
(State or other jurisdiction  
of incorporation or organization)

**87-0500306**  
(I.R.S. Employer  
Identification No.)

---

**3838 West Parkway Blvd., Salt Lake City, Utah 84120**

(Address of principal executive offices, Zip Code)

---

**(801) 954-7100**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  NO

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.

Large accelerated filer   
Non-accelerated filer

Accelerated filer   
Smaller reporting company   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of shares outstanding of the registrant's common stock as of November 2, 2018 was 23,976,585

---

Table of Contents

USANA HEALTH SCIENCES, INC.

FORM 10-Q

For the Quarterly Period Ended September 29, 2018

INDEX

	Page
<b><u>PART I. FINANCIAL INFORMATION</u></b>	
<u>Item 1</u>	
<u>Financial Statements (unaudited)</u>	
<u>Condensed Consolidated Balance Sheets</u>	3
<u>Condensed Consolidated Statements of Comprehensive Income</u>	4
<u>Condensed Consolidated Statements of Stockholders' Equity</u>	5
<u>Condensed Consolidated Statements of Cash Flows</u>	6
<u>Notes to Condensed Consolidated Financial Statements</u>	8-18
<u>Item 2</u>	
<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	20-28
<u>Item 3</u>	
<u>Quantitative and Qualitative Disclosures About Market Risk</u>	29
<u>Item 4</u>	
<u>Controls and Procedures</u>	29
<b><u>PART II. OTHER INFORMATION</u></b>	
<u>Item 1</u>	
<u>Legal Proceedings</u>	29
<u>Item 1A</u>	
<u>Risk Factors</u>	29
<u>Item 2</u>	
<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	30
<u>Item 3</u>	
<u>Defaults Upon Senior Securities</u>	30
<u>Item 4</u>	
<u>Mine Safety Disclosures</u>	30
<u>Item 5</u>	
<u>Other Information</u>	30
<u>Item 6</u>	
<u>Exhibits</u>	30
<u>Signatures</u>	31

Table of Contents**PART I. FINANCIAL INFORMATION****Item 1. Financial Statements****USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED BALANCE SHEETS**

(in thousands, except par value)

(unaudited)

	As of December 30, 2017	As of September 29, 2018
<b>ASSETS</b>		
Current assets		
Cash and cash equivalents	\$ 247,131	\$ 239,751
Securities held-to-maturity, net		81,673
Inventories	62,918	81,110
Prepaid expenses and other current assets	30,110	32,228
Total current assets	340,159	434,762
Property and equipment, net	102,847	93,555
Goodwill	17,417	16,829
Intangible assets, net	35,154	32,217
Deferred tax assets	2,859	3,771
Other assets	20,833	18,247
	\$ 519,269	\$ 599,381
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities		
Accounts payable	\$ 11,787	\$ 14,467
Other current liabilities	129,396	138,419
Total current liabilities	141,183	152,886
Deferred tax liabilities	13,730	9,848
Other long-term liabilities	1,146	1,058
Stockholders' equity		
Common stock, \$0.001 par value; Authorized 50,000 shares, issued and outstanding 24,024 as of December 30, 2017 and 24,201 as of September 29, 2018	24	24
Additional paid-in capital	76,542	83,216
Retained earnings	288,070	362,250
Accumulated other comprehensive income (loss)	(1,426)	(9,901)
Total stockholders' equity	363,210	435,589

\$ 519,269 \$ 599,381

The accompanying notes are an integral part of these statements.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands, except per share data)

(unaudited)

	Quarter Ended		Nine Months Ended	
	September 30, 2017	September 29, 2018	September 30, 2017	September 29, 2018
Net sales	\$ 261,765	\$ 296,767	\$ 774,151	\$ 890,225
Cost of sales	47,135	51,877	133,691	151,243
Gross profit	214,630	244,890	640,460	738,982
Operating expenses:				
Associate incentives	116,010	130,264	350,195	392,416
Selling, general and administrative	67,263	69,112	193,653	206,781
Total operating expenses	183,273	199,376	543,848	599,197
Earnings from operations	31,357	45,514	96,612	139,785
Other income (expense):				
Interest income	571	1,269	1,644	3,140
Interest expense	(10)	(8)	(31)	(27)
Other, net	129	(249)	19	(851)
Other income (expense), net	690	1,012	1,632	2,262
Earnings before income taxes	32,047	46,526	98,244	142,047
Income taxes	8,278	15,486	29,858	48,154
Net earnings	\$ 23,769	\$ 31,040	\$ 68,386	\$ 93,893
Earnings per common share				
Basic	\$ 0.98	\$ 1.28	\$ 2.80	\$ 3.88
Diluted	\$ 0.97	\$ 1.24	\$ 2.75	\$ 3.80
Weighted average common shares outstanding				
Basic	24,283	24,269	24,462	24,179
Diluted	24,588	25,001	24,871	24,705
Comprehensive income:				
Net earnings	\$ 23,769	\$ 31,040	\$ 68,386	\$ 93,893

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Other comprehensive income (loss), net of tax:				
Foreign currency translation adjustment	2,941	(6,381)	10,153	(10,087)
Tax benefit (expense) related to foreign currency translation adjustment	(625)	344	(2,601)	1,612
Other comprehensive income (loss), net of tax	2,316	(6,037)	7,552	(8,475)
Comprehensive income	\$ 26,085	\$ 25,003	\$ 75,938	\$ 85,418

The accompanying notes are an integral part of these statements.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY

(in thousands)

(unaudited)

For the nine months ended September 30, 2017

	Shares	Common Stock Value	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total
Balance at December 31, 2016	24,485	\$ 24	\$ 71,505	\$ 265,405	\$ (11,647)	325,287
Net earnings				68,386		68,386
Other comprehensive income (loss), net of tax					7,552	7,552
Equity-based compensation expense			11,711			11,711
Common stock repurchased and retired	(865)	(1)	(10,129)	(39,870)		(50,000)
Common stock issued under equity award plans	326	1				1
Tax withholding for net-share settled equity awards			(125)			(125)
Balance at September 30, 2017	23,946	\$ 24	\$ 72,962	\$ 293,921	\$ (4,095)	362,812

For the nine months ended September 29, 2018

	Shares	Common Stock Value	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total
Balance at December 30, 2017	24,024	\$ 24	\$ 76,542	\$ 288,070	\$ (1,426)	363,210
Cumulative effect of accounting change				994		994
Balance after cumulative effect of accounting change	24,024	24	76,542	289,064	(1,426)	364,204
Net earnings				93,893		93,893

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Other comprehensive income (loss), net of tax							(8,475)	(8,475)			
Equity-based compensation expense				11,026				11,026			
Common stock repurchased and retired	(217)			(4,883)		(20,707)		(25,590)			
Common stock issued under equity award plans	394										
Tax withholding for net-share settled equity awards				(376)				(376)			
Disgorgement of short-swing stock profits				907				907			
Balance at September 29, 2018	24,201	\$	24	\$	83,216	\$	362,250	\$	(9,901)	\$	435,589

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY

(in thousands)

(unaudited)

For the three months ended September 30, 2017

	Shares	Common Stock Value	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total
Balance at July 1, 2017	24,624	\$ 24	\$ 79,507	\$ 310,022	\$ (6,411)	\$ 383,142
Net earnings				23,769		23,769
Other comprehensive income (loss), net of tax					2,316	2,316
Equity-based compensation expense			3,709			3,709
Common stock repurchased and retired	(865)	(1)	(10,129)	(39,870)		(50,000)
Common stock issued under equity award plans	187	1				1
Tax withholding for net-share settled equity awards			(125)			(125)
Balance at September 30, 2017	23,946	\$ 24	\$ 72,962	\$ 293,921	\$ (4,095)	\$ 362,812

For the three months ended September 29, 2018

	Shares	Common Stock Value	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total
Balance at June 30, 2018	24,220	\$ 24	\$ 83,542	\$ 349,579	\$ (3,864)	\$ 429,281
Net earnings				31,040		31,040
Other comprehensive income (loss), net of tax					(6,037)	(6,037)
Equity-based compensation expense			3,968			3,968
Common stock repurchased and retired	(178)		(4,278)	(18,369)		(22,647)
	159					

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Common stock issued under  
equity award plans

Tax withholding for net-share  
settled equity awards

				(16)			(16)				
Balance at September 29, 2018	24,201	\$	24	\$	83,216	\$	362,250	\$	(9,901)	\$	435,589

The accompanying notes are an integral part of these statements.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Nine Months Ended	
	September 30, 2017	September 29, 2018
<b>Cash flows from operating activities</b>		
Net earnings	\$ 68,386	\$ 93,893
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities		
Depreciation and amortization	11,797	12,734
(Gain) loss on sale of property and equipment	8	1,804
Equity-based compensation expense	11,711	11,026
Deferred income taxes	(12,801)	(3,524)
Impairment on notes receivable		(658)
Changes in operating assets and liabilities:		
Inventories	4,556	(21,938)
Prepaid expenses and other assets	6,343	(2,396)
Accounts payable	550	2,855
Other liabilities	(21,909)	17,897
<b>Net cash provided by (used in) operating activities</b>	<b>68,641</b>	<b>111,693</b>
<b>Cash flows from investing activities</b>		
Receipts on notes receivable	259	4,801
Proceeds from the settlement of net investment hedges		739
Purchases of investment securities held-to-maturity		(81,673)
Proceeds from sale of property and equipment	16	381
Purchases of property and equipment	(9,168)	(8,862)
<b>Net cash provided by (used in) investing activities</b>	<b>(8,893)</b>	<b>(84,614)</b>
<b>Cash flows from financing activities</b>		
Repurchase of common stock	(50,000)	(25,590)
Proceeds from disgorgement of short-swing stock profits		907
Borrowings on line of credit	3,500	
Payments on line of credit	(3,500)	
Payments related to tax withholding for net-share settled equity awards	(125)	(376)
<b>Net cash provided by (used in) financing activities</b>	<b>(50,125)</b>	<b>(25,059)</b>
Effect of exchange rate changes on cash, cash equivalents and restricted cash	6,481	(9,784)
<b>Net increase (decrease) in cash, cash equivalents and restricted cash</b>	<b>16,104</b>	<b>(7,764)</b>
Cash, cash equivalents, and restricted cash, at beginning of period	178,952	250,535

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Cash, cash equivalents, and restricted cash at end of period	\$	195,056	\$	242,771
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets				
Cash and equivalents	\$	191,745	\$	239,751
Restricted cash included in prepaid expenses and other current assets		305		108
Restricted cash included in other assets		3,006		2,912
Total cash, cash equivalents, and restricted cash	\$	195,056	\$	242,771
Supplemental disclosures of cash flow information				
Cash paid during the period for:				
Interest	\$	9	\$	5
Income taxes		40,532		59,244
Cash received during the period for:				
Income tax refund		4,700		2,451
Non-cash investing activities:				
Credits on notes receivable		412		
Accrued purchases of property and equipment		202		50

The accompanying notes are an integral part of these statements.

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE A ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION**

USANA Health Sciences, Inc. develops and manufactures high-quality nutritional and personal care/skincare products that are sold internationally through a global network marketing system, which is a form of direct selling. The Condensed Consolidated Financial Statements include the accounts and operations of USANA Health Sciences, Inc., a Utah corporation and its wholly-owned subsidiaries (collectively, the Company or USANA) in two geographic regions: Asia Pacific, and Americas and Europe. Asia Pacific is further divided into three sub-regions: Greater China, Southeast Asia Pacific, and North Asia. Greater China includes Hong Kong, Taiwan and China; Southeast Asia Pacific includes Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand, and Indonesia; North Asia includes Japan, and South Korea. Americas and Europe includes the United States, Canada, Mexico, Colombia, the United Kingdom, France, Germany, Spain, Italy, Romania, Belgium, and the Netherlands. All intercompany accounts and transactions have been eliminated in consolidation.

The condensed consolidated balance sheet as of December 30, 2017, derived from audited consolidated financial statements, and the unaudited interim consolidated financial information of the Company have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures that are normally included in financial statements that have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. In the opinion of management, the accompanying interim condensed consolidated financial information contains all adjustments, consisting only of normal recurring adjustments that are necessary to state fairly the Company's financial position as of September 29, 2018 and results of operations for the quarters and nine months ended September 30, 2017 and September 29, 2018.

The interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto that are included in the Company's Annual Report on Form 10-K for the year ended December 30, 2017. The results of operations for the nine months ended September 29, 2018, are not necessarily indicative of the results that may be expected for the fiscal year ending December 29, 2018.

**Recent Accounting Pronouncements**

*Adopted accounting pronouncements*

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

In May 2014, the Financial Accounting Standards Board ( FASB ) issued Accounting Standards Update ( ASU ) No. 2014-09, Revenue from Contracts with Customers (Topic 606). Also referred to as ASC 606, this update replaces existing revenue recognition guidance with a single comprehensive revenue model for entities to use in accounting for revenue arising from contracts with customers. ASC 606 includes a five-step process by which entities recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which an entity expects to be entitled in exchange for those goods or services. This standard also requires enhanced disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.

The Company adopted ASC 606 effective at the beginning of fiscal 2018 and applied the modified retrospective approach. Accordingly, the Company recognized the cumulative effect of initially applying ASC 606 as an adjustment to the fiscal 2018 opening balance of retained earnings. The comparative information has not been restated and continues to be presented according to accounting standards in effect for those periods. The adoption of ASC 606 did not have a material impact on the Company's consolidated financial statements. As a result of the adoption of ASC 606, the Company updated its accounting policies related to revenue recognition. See Note B **Revenue Recognition** for additional information regarding the Company's revenue recognition policies under the new standard.

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE A ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION - CONTINUED**

Under ASC 606, the Company made a change in the timing for recognizing revenue on orders that have shipped but have not been delivered at period end. Under the new standard, revenue is recognized when the customer obtains control of the goods and considering the indicators used to determine when control has passed to the customer, the Company has concluded that control transfers upon shipment. Therefore, revenue and related expense items including cost of goods sold and Associate incentives on orders that have shipped but have not been delivered at period end are no longer deferred. Subsequent to the period of adoption, there has been no material impact on net income and related per-share amounts.

In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule is effective on November 5, 2018. The Company is in the process of evaluating the impact of the final rule on its consolidated financial statements.

*Issued accounting pronouncements not yet adopted*

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). ASU 2016-02 is intended to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Additionally, the ASU will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases, including qualitative and quantitative requirements. The update requires lessees to apply a modified retrospective approach for recognition and disclosure, beginning with the earliest period presented. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842) Targeted Improvements, which allows an additional transition method to adopt the new lease standard at the adoption date, as compared to the beginning of the earliest period presented, and recognize a cumulative-effect adjustment to the beginning balance of retained earnings in the period of adoption. The Company will adopt ASU 2016-02 in the first quarter of 2019, specifically, using the alternative transition method. The Company is currently in the process of accumulating and evaluating all the necessary information required to properly account for its lease portfolio under the new standard. The Company is also in the process of implementing changes to its systems and processes in conjunction with its review of lease agreements to support the ongoing accounting and disclosure requirements. Although the Company is in the process of evaluating the impact of adoption of the ASU on its consolidated financial statements, the Company currently believes the most significant change will be related to the recognition of right-of-use assets and lease liabilities on the Company's balance sheet for facility lease agreements.

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. ASU 2017-12 better aligns an entity's risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. To satisfy that objective, the amendments expand and refine hedge accounting for both non-financial and financial risk components, and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. For public business entities, the amendments in this ASU are effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect the adoption of ASU 2017-12 will have a material impact on its consolidated financial statements.

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE A ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION - CONTINUED**

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 modifies the disclosure requirements for fair value measurements. The modifications removed the following disclosure requirements: (i) the amount of, and reasons for, transfers between Level 1 and Level 2 of the fair value hierarchy; (ii) the policy for timing of transfers between levels; and (iii) the valuation processes for Level 3 fair value measurements. This ASU added the following disclosure requirements: (i) the changes in unrealized gains and losses for the period included in other comprehensive income ( OCI ) for recurring Level 3 fair value measurements held at the end of the reporting period; and (ii) the range and weighted average of significant observable inputs used to develop Level 3 fair value measurements. The amendments in this Update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. The Company does not expect the adoption of ASU 2018-13 will have a material impact on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The capitalized implementation costs of a hosting arrangement that is a service contract will be expensed over the term of the hosting arrangement. For public business entities, the amendments in this ASU are effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period. The amendments can be applied either retrospectively or prospectively to all implementation costs incurred after the adoption date. The Company does not expect the adoption of ASU 2018-15 will have a material impact on its consolidated financial statements.

**NOTE B REVENUE RECOGNITION**

Revenue is recognized when, or as, control of a promised product or service transfers to a customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring those products or services. Revenue excludes taxes that have been assessed by governmental authorities and that are directly imposed on revenue-producing transactions between the Company and its customers, including sales, use, value-added, and some excise taxes. Revenue recognition is evaluated through the following five-step process:

1) identification of the contract with a customer;

- 2) identification of the performance obligations in the contract;
- 3) determination of the transaction price;
- 4) allocation of the transaction price to the performance obligations in the contract; and
- 5) recognition of revenue when or as a performance obligation is satisfied.

*Product Revenue*

A majority of the Company's sales are for products sold at a point in time and shipped to customers, for which control is transferred as goods are delivered to the third party carrier for shipment. The Company receives payment, primarily via credit card, for the sale of products at the time customers place orders and payment is required prior to shipment.

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE B REVENUE RECOGNITION - CONTINUED**

The Company's product sales contracts include terms that could cause variability in the transaction price for items such as discounts, credits, or sales returns. Accordingly, the transaction price for product sales includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will not occur. At the time of sale, the Company estimates a refund liability for the variable consideration based on historical experience.

Initial product orders with a new customer may include multiple performance obligations related to sales discounts earned under the Company's initial order reward program. Under this program, the customer receives an option to apply the discounts earned on the initial order to two subsequent Auto Orders, which conveys a material right to the customer. As such, the initial order transaction price is allocated to each separate performance obligation based on its relative standalone selling price and recognized as revenue as each performance obligation is satisfied.

Associate incentives represent consideration paid to a customer and include all forms of commissions, and other incentives paid to our Associates. With the exception of commissions paid to Associates on personal purchases, which are considered a sales discount and are reported as a reduction to net sales, the incentives are paid for distinct services related to the Company's product sales and are recorded as an expense when revenue for the goods is recognized.

Shipping and handling activities are performed after the customer obtains control of the goods transferred. The Company accounts for these activities as fulfillment costs. Therefore, the Company recognizes the costs of these activities when revenue for the goods is recognized. Shipping and handling costs are included in cost of sales for all periods presented.

With respect to will-call orders, the Company periodically assesses the likelihood that customers will exercise their contractual right to pick up orders and revenue is recognized when the likelihood is estimated to be remote.

*Other Revenue*

Other types of revenue include fees for access to online customer service applications and annual account renewal fees for Associates, for which control is transferred over time as services are delivered and are recognized as revenue on a straight-line basis over the term of the respective contracts.

*Revenue Disaggregation*

Disaggregation of revenue by geographical region and major product line is included in Segment Information in Note L.

*Contract Balances*

Contract liabilities, which are recorded within Other current liabilities in the condensed consolidated balance sheets, primarily relate to deferred revenue for product sales for customer payments received in advance of shipment, for outstanding material rights under the initial order program, and for services where control is transferred over time as services are delivered.

The following table provides information about contract liabilities from contracts with customers, including significant changes in the contract liabilities balances during the period.

	<b>Nine Months Ended September 29, 2018</b>	
Contract liabilities at beginning of period	\$	14,417
Increase due to deferral of revenue		17,601
Decreases due to recognition of revenue		(14,141)
Contract liabilities at end of period	\$	17,877

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

## NOTE C FAIR VALUE MEASURES

The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are:

- Level 1 inputs are quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date.
- Level 2 inputs are from other than quoted market prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 inputs are unobservable and are used to measure fair value in situations where there is little, if any, market activity for the asset or liability at the measurement date.

As of the dates indicated, the following financial assets and liabilities were measured at fair value on a recurring basis using the type of inputs shown:

	December 30, 2017	Fair Value Measurements Using		
		Level 1	Inputs Level 2	Level 3
Money market funds included in cash equivalents	\$ 106,090	\$ 106,090	\$	\$
Foreign currency contracts included in other current liabilities	(139)		(139)	
	\$ 105,951	\$ 106,090	\$ (139)	\$

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

	September 29, 2018	Fair Value Measurements Using		
		Level 1	Inputs Level 2	Level 3
Money market funds included in cash equivalents	\$ 128,418	\$ 128,418	\$	\$
Foreign currency contracts included in other current liabilities	(93)		(93)	
	\$ 128,325	\$ 128,418	\$ (93)	\$

There were no transfers of financial assets or liabilities between levels of the fair value hierarchy for the periods indicated.

The majority of the Company's non-financial assets, which include goodwill, intangible assets, and property and equipment, are not required to be carried at fair value on a recurring basis. However, if certain triggering events occur (or tested at least annually for goodwill and indefinite-lived intangibles) such that a non-financial asset is required to be evaluated for impairment, an impairment charge is recorded to reduce the carrying value to the fair value, if the carrying value exceeds the fair value. At December 30, 2017 and September 29, 2018, there were no non-financial assets measured at fair value on a non-recurring basis.

The Company's financial instruments include cash equivalents, securities held-to-maturity, accounts receivable, restricted cash, notes receivable, and accounts payable. The recorded values of cash equivalents, accounts receivable, restricted cash, and accounts payable approximate their fair values, based on their short-term nature. Historically, the carrying value of the notes receivable approximated fair value because the variable interest rates in the notes reflected current market rates. During the year ended December 30, 2017, an impairment was recorded on a note receivable (discussed in Note G) based on the estimated recoverable amount using Level 3 inputs, which approximates fair value.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

**NOTE C FAIR VALUE MEASURES - CONTINUED**

Securities held-to-maturity consist of corporate bonds, commercial paper, and U.S. treasuries. The fair value of corporate bonds, commercial paper, and U.S. treasuries are priced using quoted market prices for similar instruments or non-binding market prices that are corroborated by observable market data, which is considered to be a Level 2 input. The carrying values of these corporate bonds, commercial paper, and U.S. treasuries approximate their fair values due to their short-term maturities.

**NOTE D INVESTMENTS**

The carrying amount, gross unrealized holding gains, gross unrealized holding losses, and fair value of securities held-to-maturity by major security type and class of security were as follows:

	Amortized Cost	As of September 29, 2018		Estimated Fair Value
		Unrecognized Holding Gains	Unrecognized Holding Losses	
Corporate bonds	60,743	5	(24)	60,724
U.S. treasuries	14,981		(1)	14,980
Commercial paper	5,949			5,949
Total securities held-to-maturity	\$ 81,673	\$ 5	\$ (25)	\$ 81,653

All held-to-maturity securities as of September 29, 2018 mature within one year.

**NOTE E INVENTORIES**

Inventories consist of the following:

	December 30, 2017	September 29, 2018
Raw materials	\$ 20,737	\$ 22,066
Work in progress	8,461	14,318
Finished goods	33,720	44,726
	\$ 62,918	\$ 81,110

**NOTE F INTANGIBLE ASSETS**

The Company performed its annual goodwill impairment test during the third quarter of 2018. The Company performed a qualitative assessment of each reporting unit and determined that it was not more-likely-than-not that the fair value of any reporting unit was less than its carrying amount. As a result, no impairments of goodwill were recognized.

The Company also performed its annual indefinite-lived intangible asset impairment test during the third quarter of 2018. The Company performed a qualitative assessment of the indefinite-lived intangible asset and determined that it was not more-likely-than-not that the fair value of the indefinite-lived intangible asset was less than the carrying amount. As a result, no impairment of the indefinite-lived intangible asset was recognized.

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE G OTHER ASSETS**

Other assets consist primarily of land use rights related to a production facility in China. At December 30, 2017, other assets also included a secured loan to the former supplier of the Company's nutrition bars. The Company extended non-revolving credit to this former supplier to allow them to acquire equipment that was necessary to manufacture the USANA nutrition bars, which was secured by the equipment. This relationship was intended to provide improved supply chain stability for USANA and create a mutually beneficial relationship between the parties. Interest accrued at an annual interest rate of LIBOR plus 400 basis points. The note had a maturity date of February 1, 2024 and was to be repaid by a combination of cash payments and credits for the manufacture of USANA's nutrition bars.

A loan is considered impaired when, based on current information and events; it is probable that the Company will be unable to collect the scheduled payments in accordance with the contractual terms of the loan. Factors considered in determining impairment include payment status, collateral value and the probability of collecting payments when due. During the first half of 2017, the Company experienced challenges with the former supplier of nutrition bars and subsequently determined to no longer use this supplier. The Company evaluated the recoverability of the note receivable from this supplier and recorded impairments totaling \$2,734 during the year ended December 30, 2017. The total contractual unpaid principal balance, including accrued unpaid interest on the note receivable from this supplier as of December 30, 2017 was \$6,734. During April 2018, the Company reached a settlement with the supplier to terminate the relationship and received \$4,800 in cash as payment in full under the terms of the settlement.

**NOTE H LINE OF CREDIT**

The Company has a \$75,000 line of credit with Bank of America. Interest is computed at the bank's Prime Rate or LIBOR, adjusted by features specified in the Credit Agreement. The collateral for this line of credit is the pledge of the capital stock of certain subsidiaries of the Company, pursuant to a separate pledge agreement with the bank. On February 19, 2016, the Company entered into an Amended and Restated Credit Agreement with Bank of America, which extends the term of the Credit Agreement to April 27, 2021 and increases the Company's consolidated rolling four-quarter adjusted EBITDA covenant to \$100,000 or greater and its ratio of consolidated funded debt to adjusted EBITDA of 1.0 at the end of each quarter.

The adjusted EBITDA under the Credit Agreement is modified for certain non-cash expenses. Any existing bank guarantees are considered a reduction of the overall availability of credit and part of the covenant calculation under the credit agreement. This resulted in a \$4,273 and \$6,602 reduction in the available borrowing limit as of December 30, 2017 and September 29, 2018, respectively, due to existing normal course of business guarantees in certain markets.

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

There was no outstanding debt on this line of credit at December 30, 2017 or at September 29, 2018. The Company will be required to pay any balance on this line of credit in full at the time of maturity in April 2021 unless the line of credit is replaced or terms are renegotiated.

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE I CONTINGENCIES**

The Company is involved in various lawsuits, claims, and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company records a liability when a particular contingency is probable and estimable. The Company faces contingencies that are reasonably possible to occur; however, they cannot currently be estimated. While complete assurance cannot be given to the outcome of these proceedings, management does not currently believe that any of these matters, individually or in the aggregate, will have a material adverse effect on the Company's financial condition, liquidity or results of operations.

On February 7, 2017, the Company disclosed in a Current Report on Form 8-K filed with the SEC that it is conducting a voluntary internal investigation regarding its BabyCare operations in China. In connection with this investigation, the Company expects to continue to incur costs in conducting the on-going review and investigation, in responding to requests for information in connection with any government investigations and in defending any potential civil or governmental proceedings that are instituted against it or any of its current or former officers or directors. The Company has voluntarily contacted the SEC and the United States Department of Justice to advise both agencies that an internal investigation is underway and intends to provide additional information to both agencies as the investigation progresses. Because the internal investigation is ongoing, the Company cannot predict the duration, scope, or result of the investigation. One or more governmental actions could be instituted in respect of the matters that are the subject of the internal investigation, and such actions, if brought, may result in judgments, settlements, fines, penalties, injunctions, cease and desist orders, criminal penalties, or other relief.

On February 13, 2017, a purported shareholder class action lawsuit (*Rumbaugh v. USANA Health Sciences Inc., et al.*, Case No. 2:17-cv-00106) was filed in the United States District Court for the District of Utah by April Rumbaugh, a purported shareholder of USANA, alleging that the Company failed to disclose that (i) the Company's BabyCare subsidiary had engaged in improper reimbursement practices in China, (ii) these practices constituted violations of the Foreign Corrupt Practices Act or FCPA, (iii) as such, the Company's China revenues were in part the product of unlawful conduct and unlikely to be sustainable, and (iv) the foregoing conduct, when it became known, was likely to subject the Company to significant regulatory scrutiny. On behalf of herself and a putative class of purchasers of USANA stock between March 14, 2014 and February 7, 2017, the plaintiff asserted claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the Exchange Act) and Rule 10b-5 promulgated thereunder. The plaintiff sought, among other things, an award of damages, interest, reasonable attorneys' fees, expert fees, and other costs. The lawsuit named as defendants the Company; its former Co-Chief Executive Officer, David A. Wentz; and our Chief Leadership Development Officer, Paul A. Jones. On June 2, 2017, the court appointed Chi Wah On (another purported shareholder of USANA) as lead plaintiff. On August 4, 2017, lead plaintiff filed a consolidated amended complaint seeking similar relief. This new complaint asserted additional allegations and added the Company's Chief Executive Officer, Kevin G. Guest, and Chief Financial Officer, G. Douglas Hekking, as defendants. On September 18, 2017, the Company filed a motion to dismiss the amended complaint, and briefing was completed on November 8, 2017. The motion to dismiss was argued on April 25, 2018. Subsequent to September 29, 2018, on October 16, 2018, the United States District Court for the District of Utah dismissed the action with prejudice.

**NOTE J DERIVATIVE FINANCIAL INSTRUMENTS**

The Company's risk management strategy includes the select use of derivative instruments to reduce the effects of volatility in foreign currency exchange exposure on operating results and cash flows. In accordance with the Company's risk management policies, the Company does not hold or issue derivative instruments for trading or speculative purposes.

The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values. When the Company becomes a party to a derivative instrument and intends to apply hedge accounting, the Company formally documents the hedge relationship and the risk management objective for undertaking the hedge, the nature of risk being hedged, and the hedged transaction, which includes designating the instrument for financial reporting purposes as a fair value hedge, a cash flow hedge, or a net investment hedge. The Company also documents how the hedging instrument's effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness.

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE J DERIVATIVE FINANCIAL INSTRUMENTS - CONTINUED**

The Company periodically uses derivative hedging instruments to hedge its net investment in its non U.S. subsidiaries designed to hedge a portion of the foreign currency exposure that arises on translation of the foreign subsidiaries into U.S. dollars. The effective portion of gains and losses attributable to these net investment hedges is recorded to foreign currency translation adjustment ( FCTA ) within accumulated other comprehensive income (loss) ( AOCI ) to offset the change in the carrying value of the net investment being hedged, and will subsequently be reclassified to net earnings in the period in which the hedged investment is either sold or substantially liquidated.

As of December 30, 2017, there were no derivatives outstanding for which the Company has applied hedge accounting. During the second quarter of 2018, the Company entered into and settled a forward contract designated as a net investment hedge with a notional value of \$105,000 and realized a net gain of \$739, which is reflected in the FCTA within AOCI. The Company assessed hedge effectiveness determining the hedged instrument was highly effective and recorded no ineffectiveness. As of September 29, 2018, there were no derivatives outstanding for which the Company has applied hedge accounting.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

**NOTE K COMMON STOCK AND EARNINGS PER SHARE**

Basic earnings per share are based on the weighted-average number of shares outstanding for each period. Shares that have been repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that are outstanding for the calculation of basic earnings per share based on the time they were outstanding in any period. Diluted earnings per common share are based on shares that are outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that are included in the diluted earnings per share calculations under the treasury stock method include equity awards that are in-the-money but have not yet been exercised.

The following is a reconciliation of the numerator and denominator used to calculate basic earnings per share and diluted earnings per share for the periods indicated:

	Quarter Ended		Nine Months Ended	
	September 30, 2017	September 29, 2018	September 30, 2017	September 29, 2018
Net earnings available to common shareholders	\$ 23,769	\$ 31,040	\$ 68,386	\$ 93,893
Weighted average common shares outstanding - basic	24,283	24,269	24,462	24,179
Dilutive effect of in-the-money equity awards	305	732	409	526
Weighted average common shares outstanding - diluted	24,588	25,001	24,871	24,705
Earnings per common share from net earnings - basic	\$ 0.98	\$ 1.28	\$ 2.80	\$ 3.88
Earnings per common share from net earnings - diluted	\$ 0.97	\$ 1.24	\$ 2.75	\$ 3.80

Equity awards for the following shares were not included in the computation of diluted EPS due to the fact that their effect would be anti-dilutive:

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Quarter Ended		Nine Months Ended	
September 30, 2017	September 29, 2018	September 30, 2017	September 29, 2018
2,035		2,091	601

During the quarter ended September 30, 2017 and September 29, 2018, the Company repurchased and retired 865 shares and 178 shares for \$50,000 and \$22,647, respectively, under the Company's share repurchase plan.

During the nine months ended September 30, 2017 and September 29, 2018, the Company repurchased and retired 865 shares and 217 shares for \$50,000 and \$25,590, respectively under the Company's share repurchase plan. The excess of the repurchase price over par value is allocated between additional paid-in capital and retained earnings on a pro-rata basis. The purchase of shares under this plan reduces the number of shares outstanding in the above calculations.

As of September 29, 2018, the remaining approved repurchase amount under the stock repurchase plan was \$24,410. There currently is no expiration date on the remaining approved repurchase amount and no requirement for future share repurchases.

On October 23, 2018, the Company's Board of Directors authorized an increase in the amount available under its share repurchase plan to a total of \$150,000. The authorization is inclusive of the \$24,410 that was remaining under the prior authorization at September 29, 2018. Subsequent to September 29, 2018, and through November 2, 2018, the Company repurchased and retired 235 shares of common stock for \$26,677, at an average market price of \$113.57 per share.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

## NOTE L SEGMENT INFORMATION

USANA operates as a direct selling company that develops, manufactures, and distributes high-quality nutritional and personal care/skincare products that are sold through a global network marketing system of independent distributors ( Associates ). As such, management aggregates its operating segments into one reportable segment as management believes that the Company's segments exhibit similar long-term financial performance and have similar economic characteristics. Performance for a region or market is evaluated based on sales. No single Associate accounted for 10% or more of net sales for the periods presented. The table below summarizes the approximate percentage of total product revenue that has been contributed by the Company's nutritional, foods, and personal care/skincare products for the periods indicated.

	Quarter Ended		Nine Months Ended	
	September 30, 2017	September 29, 2018	September 30, 2017	September 29, 2018
USANA® Nutritionals	83%	83%	84%	82%
USANA Foods	9%	9%	9%	9%
Personal care/Skincare				
Sensé beautiful science®	6%	2%	6%	4%
Celavive®(1)	N/A	5%	N/A	4%

(1) We launched Celavive® in every market except China in the first quarter of 2018 and recently launched in China late in the third quarter of 2018.

Selected financial information for the Company is presented for two geographic regions: Asia Pacific, with three sub-regions under Asia Pacific, and Americas and Europe. Individual markets are categorized into these regions as follows:

- Asia Pacific
- Greater China – Hong Kong, Taiwan and China. Our business in China is conducted by BabyCare Holding, Ltd. ( BabyCare ), our wholly-owned subsidiary.

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

- Southeast Asia Pacific Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand, and Indonesia
- North Asia Japan and South Korea
- Americas and Europe United States, Canada, Mexico, Colombia, the United Kingdom, France, Germany(2), Spain(2), Italy(2), Romania(2), Belgium, and the Netherlands.

(2) We commenced operations in Germany, Spain, Italy, and Romania near the end of the second quarter of 2018.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

## NOTE L SEGMENT INFORMATION - CONTINUED

*Selected Financial Information*

Financial information by geographic region is presented for the periods indicated below:

	Quarter Ended		Nine Months Ended	
	September 30, 2017	September 29, 2018	September 30, 2017	September 29, 2018
Net Sales to External Customers				
Asia Pacific				
Greater China	\$ 131,273	\$ 160,932	\$ 399,713	\$ 486,581
Southeast Asia Pacific	52,310	58,770	151,381	169,769
North Asia	15,708	19,899	42,612	56,969
Asia Pacific Total	199,291	239,601	593,706	713,319
Americas and Europe	62,474	57,166	180,445	176,906
Consolidated Total	\$ 261,765	\$ 296,767	\$ 774,151	\$ 890,225

The following table provides further information on markets representing ten percent or more of consolidated net sales and long-lived assets, respectively:

	Quarter Ended		Nine Months Ended	
	September 30, 2017	September 29, 2018	September 30, 2017	September 29, 2018
Net sales:				
China	\$ 116,174	\$ 144,625	\$ 352,462	\$ 436,327
United States	\$ 34,183	\$ 29,790	\$ 93,219	\$ 88,734

December 30, <sup>As of</sup> September 29,

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

	2017		2018	
Long-lived assets:				
China	\$	96,248	\$	89,236
United States	\$	59,589	\$	51,218

Table of Contents

**Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following discussion and analysis of our financial condition and results of operations is presented in six sections:

- Overview
- Customers
- Current Focus and Recent Developments
- Results of Operations
- Liquidity and Capital Resources
- Forward-Looking Statements and Certain Risks

This discussion and analysis should be read in conjunction with the Unaudited Condensed Consolidated Financial Statements and Notes thereto that are contained in this quarterly report, as well as Management's Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 30, 2017, and our other filings, including Current Reports on Form 8-K, that have been filed with the SEC through the date of this report.

**Overview**

We develop and manufacture high-quality, science-based nutritional, personal care and skincare products that are distributed internationally through a network marketing system, which is a form of direct selling. We have chosen this distribution method as we believe it is more conducive to meeting our vision as a company, which is improving the overall health and nutrition of individuals and families around the world. Our customer base comprises two types of customers: Associates and Preferred Customers referred to together collectively as active Customers. Associates share in our company vision by acting as independent distributors of our products in addition to purchasing our products for their personal use. Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. As of September 29, 2018, we had approximately 615,000 active Customers worldwide. For purposes of this report, we only count as

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

active Customers those Associates and Preferred Customers who have purchased products from us at any time during the most recent three-month period.

We have ongoing operations in the following markets, which are grouped and presented as follows:

- Asia Pacific
- Greater China Hong Kong, Taiwan, and China. Our business in China is conducted by BabyCare, our wholly-owned subsidiary.
- Southeast Asia Pacific Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand, and Indonesia
- North Asia Japan and South Korea
- Americas and Europe United States, Canada, Mexico, Colombia, the United Kingdom, France, Germany(1), Spain(1), Italy(1), Romania(1), Belgium, and the Netherlands

Our primary product lines consist of (i) USANA® Nutritionals, (ii) USANA Foods, (ii) Sensé beautiful science® (Sensé), our historical line of personal care products, and (iv) Celavive®, our new innovative skincare system with our InCelligence Technology™. The USANA Nutritionals product line is further categorized into two separate classifications: Essentials and Optimizers. The following tables summarize the approximate percentage of total product revenue that has been contributed by our major product lines and our top-selling products for the current and prior-year periods as indicated:

---

(1) We commenced operations in Germany, Spain, Italy, and Romania near the end of the second quarter of 2018.

Table of Contents

<b>Product Line</b>	<b>Nine Months Ended</b>	
	<b>September 30, 2017</b>	<b>September 29, 2018</b>
<b>USANA® Nutritionals</b>		
Essentials/CellSentials	19%	17%
Optimizers	65%	65%
USANA Foods	9%	9%
Personal care/Skincare		
Sensé beautiful science®	6%	4%
Celavive®(1)	N/A	4%
All Other	1%	1%
<b>Key Product</b>		
USANA® Essentials/CellSentials	13%	11%
Proflavanol®	12%	11%
BiOmega-3	14%	14%

(1) We launched Celavive® in every market except China in the first quarter of 2018 and recently launched in China late in the third quarter of 2018.

We believe that our ability to attract and retain Associates and Preferred Customers to sell and consume our products is positively influenced by a number of factors, some of which include: the general public's heightened awareness and understanding of the connection between diet and long-term health, and a growing desire for a secondary source of income and small business ownership.

We believe that our high-quality products and our Associate Compensation Plan are the key components to attracting and retaining Associates. We periodically make changes to our Compensation Plan in an effort to ensure that our plan is among the most competitive in the industry, to encourage behavior that we believe leads to a successful business for our Associates, and to ensure that our plan provides us with leverage to grow sales and earnings.

To further support our Associates in building their businesses, we sponsor meetings and events throughout the year, which offer information about our products and our network marketing system. These meetings are designed to assist Associates in their business development and to provide a forum for interaction with our Associate leaders and members of our management team. We also provide low cost sales tools, including online sales, business management, and training tools, which we believe are an integral part of building and maintaining a successful home-based business for our Associates. Although we provide training and sales tools, we ultimately rely on our Associates to sell our products, attract new active Customers to purchase our products, and educate and train new Associates.

Because we have operations in multiple markets, with sales and expenses being generated and incurred in multiple currencies, our reported U.S. dollar sales and earnings can be significantly affected by fluctuations in currency exchange rates. In general, our operating results are affected positively by a weakening of the U.S. dollar and negatively by a strengthening of the U.S. dollar. During the nine months ended September 29, 2018, net sales outside of the United States represented 90.0% of consolidated net sales. In our net sales discussions that follow, we approximate the impact of currency fluctuations on net sales by translating current year sales at the average exchange rates in effect during the comparable periods of the prior year.



Table of Contents**Customers**

Because we sell our products exclusively to a customer base of independent Associates and Preferred Customers, we must increase the number of active Customers and/or increase the amount they spend, on average, to increase net sales. Our primary focus continues to be increasing the number of active Customers. We believe this focus is consistent with our vision of improving the overall health and nutrition of individuals and families around the world. Sales to Associates account for approximately 57% of product sales during the nine months ended September 29, 2018; the remainder of our sales are to Preferred Customers. Increases or decreases in product sales are typically the result of variations in the volume of product sold relating to fluctuations in the number of active Customers purchasing our products. The number of active Associates and Preferred Customers is, therefore, used by management as a key non-financial indicator to evaluate our operational performance.

The tables below summarize the changes in our active Customer base by geographic region. These numbers have been rounded to the nearest thousand as of the dates indicated.

Total Active Customers by Region						
	As of September 30, 2017		As of September 29, 2018		Change from Prior Year	Percent Change
<b>Asia Pacific:</b>						
Greater China	285,000	50.6%	330,000	53.7%	45,000	15.8%
Southeast Asia Pacific	106,000	18.8%	115,000	18.7%	9,000	8.5%
North Asia	34,000	6.1%	39,000	6.3%	5,000	14.7%
Asia Pacific Total	425,000	75.5%	484,000	78.7%	59,000	13.9%
<b>Americas and Europe</b>						
	138,000	24.5%	131,000	21.3%	(7,000)	(5.1)%
	563,000	100.0%	615,000	100.0%	52,000	9.2%

**Current Focus and Recent Developments**

Our primary objective is to increase the number of active Customers who purchase and use our products throughout the world. We have several strategies in place to support this objective, including:

- We successfully launched our Celavive® skincare line in every market. Our 2018 objective is to promote Celavive® to our existing Customers and to also use it to acquire a new customer demographic for USANA. With the anticipated growth from Celavive®, our goal is to grow our personal care and skincare line to an estimated run rate of 10% of net sales by the end of fiscal 2018.
- We completed the development of our new WeChat platform in China during the second quarter of 2018 and made it available to our China Customers during the third quarter of 2018. WeChat is a Chinese multi-purpose messaging and social media app that is widely thought of as China's app for everything because of its wide range of

functionality. This platform is part of our Customer experience initiative and is intended to make it easier for Customers in China to do business as they will be able to use the app to introduce USANA to new customers, complete sales of products and enroll new customers.

- We continue to develop and deploy information technology tools across the enterprise, including a new social sharing platform. This platform, which we began rolling out during the first quarter of 2018, allows our Associates to more fully utilize social media to promote USANA products and interact directly with Customers and potential customers. In particular, we are utilizing our social selling platform in connection with the launch of Celavive® around the world.

During the quarter, we held our International Convention in Salt Lake City, where a number of our Associates gathered to celebrate their success, engage with management and receive additional training.

Table of Contents

**Non-GAAP Financial Measures**

Regulation S-K Item 10(e), Use of non-GAAP Financial Measures in Commission Filings, and other SEC regulations define and prescribe the conditions for use of certain non-GAAP financial information. Constant and local currency net sales, earnings, EPS and other currency-related financial information (collectively, Financial Results ) are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates and help facilitate period-to-period comparisons of our Financial Results and thus provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount for the current period to the prior-year period's Financial Results. A reconciliation of these non-GAAP financial measures accompanies any reference to them in the presentation in the accompanying financial statements and notes thereto. Management believes that the non-GAAP financial measures assist management and investors in evaluating, and comparing from period to period, results from ongoing operations in a meaningful and consistent manner while also highlighting meaningful trends in the results of operations. These measures are used in addition to and in conjunction with results presented in accordance with GAAP. Investors should rely primarily on our GAAP results and use non-GAAP financial measures only supplementally in making investment decisions.

**Results of Operations**

*Summary of Financial Results*

Net sales for the third quarter of 2018 increased 13.4% to \$296.8 million, an increase of \$35.0 million, compared with the third quarter of 2017. This increase was driven by several factors, including: (i) growth in active Customers, which increased 9.2% year-over-year to 615,000, and (ii) our new Celavive® line, which contributed approximately \$9.5 million in incremental sales. This increase was partially offset by unfavorable changes in currency exchange rates that reduced net sales for the third quarter by \$6.2 million.

Net earnings for the third quarter of 2018 increased 30.6% to \$31.0 million, an increase of \$7.3 million, compared with the third quarter of 2017. The increase in net earnings was primarily the result of higher net sales, and lower relative operating expenses.

Table of Contents**Quarters Ended September 30, 2017 and September 29, 2018***Net Sales*

The following table summarizes the changes in our net sales by geographic region for the fiscal quarters ended as of the dates indicated:

	Net Sales by Region (in thousands) Quarter Ended				Change from prior year	Percent change	Currency impact on sales	Percent change excluding currency impact
	September 30, 2017		September 29, 2018					
<b>Asia Pacific</b>								
Greater China	\$ 131,273	50.1%	\$ 160,932	54.2%	\$ 29,659	22.6%	\$ (3,221)	25.0%
Southeast Asia Pacific	52,310	20.0%	58,770	19.8%	6,460	12.3%	(1,942)	16.1%
North Asia	15,708	6.0%	19,899	6.7%	4,191	26.7%	182	25.5%
Asia Pacific Total	199,291	76.1%	239,601	80.7%	40,310	20.2%	(4,981)	22.7%
<b>Americas and Europe</b>								
	62,474	23.9%	57,166	19.3%	(5,308)	(8.5)%	(1,236)	(6.5)%
	\$ 261,765	100.0%	\$ 296,767	100.0%	\$ 35,002	13.4%	\$ (6,217)	15.7%

*Asia Pacific:* The increase in constant currency net sales in Greater China continues to be driven by growth in Mainland China, where local currency net sales increased 27.0%. The increase in constant currency net sales in Southeast Asia Pacific was driven by double digit local currency growth in several markets, including Malaysia, Philippines, Australia, and New Zealand. The increase in constant currency net sales in North Asia continues to be driven by growth in South Korea, where local currency net sales increased 25.6%, and the number of active Customers increased 15.6%.

*Americas and Europe:* The decrease in constant currency net sales in this region was driven by decreases in the U.S. and Mexico, where sales decreased 12.9% and 11.9%, respectively. Net sales in the U.S. were down compared with the prior year period due to higher sales related to the introduction of our Celavive® product line at our 2017 International Convention. Sustainable customer growth remains our top priority for each of our reporting regions.

*Gross Profit*

Gross profit increased 50 basis points to 82.5% of net sales for the third quarter of 2018, from 82.0% in the prior year. This increase can be attributed to changes in sales mix by market, leverage from higher sales on fixed costs, and lower relative freight costs, as well as annual price adjustments. These increases were partially offset by higher reserves for inventory obsolescence and costs associated with Celavive®, which

carries a higher relative cost than our previous skincare line.

*Associate Incentives*

Associate incentives were 43.9% of net sales for the third quarter of 2018, compared with 44.3% in the prior year. This decrease can be primarily attributed to sales from Celavive®, which has a lower incentive payout as compared to our other product categories.

*Selling, General and Administrative Expenses*

In absolute terms, our selling, general and administrative expense increased \$1.8 million during the third quarter of 2018

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

### Table of Contents

when compared with the same period of the prior year. This increase can be attributed to higher employee related costs in the current year period. This absolute increase was partially offset by a reduction in expense related to China and our internal investigation and an impairment charge related to our note receivable from a former third-party supplier in the prior-year period.

### *Income Taxes*

Income taxes were 33.3% of earnings in the third quarter of 2018 compared with 25.8% of earnings in the prior year. The higher effective tax rate for the third quarter compared with the same period of the prior-year is primarily due to higher excess tax benefits from equity award exercises recognized during the prior year quarter. Our effective tax rate, on a year-over-year basis, is not (and will not be) comparable during 2018 because of the impact of U.S. tax reform.

### *Diluted Earnings Per Share*

Diluted earnings per share increased 27.8% in the third quarter of 2018 when compared with the prior-year quarter. This increase was due to higher net earnings offset, in part, by a higher diluted share count.

### **Nine Months Ended September 30, 2017 and September 29, 2018**

### *Net Sales*

The following table summarizes the changes in our net sales by geographic region for the periods ended as of the dates indicated:

	<b>Net Sales by Region (in thousands)</b>				<b>Change from prior year</b>	<b>Percent change</b>	<b>Currency impact on sales</b>	<b>Percent change excluding currency impact</b>
	<b>September 30, 2017</b>	<b>Nine Months Ended</b>		<b>September 29, 2018</b>				
<b>Asia Pacific</b>								
Greater China	\$ 399,713	51.6%	\$ 486,581	54.7%	\$ 86,868	21.7%	\$ 18,481	17.1%
<b>Southeast Asia</b>								
Pacific	151,381	19.6%	169,769	19.0%	18,388	12.1%	916	11.5%
North Asia	42,612	5.5%	56,969	6.4%	14,357	33.7%	2,203	28.5%
<b>Asia Pacific Total</b>	<b>593,706</b>	<b>76.7%</b>	<b>713,319</b>	<b>80.1%</b>	<b>119,613</b>	<b>20.1%</b>	<b>21,600</b>	<b>16.5%</b>
<b>Americas and Europe</b>								
	180,445	23.3%	176,906	19.9%	(3,539)	(2.0)%	1,043	(2.5)%
	\$ 774,151	100.0%	\$ 890,225	100.0%	\$ 116,074	15.0%	\$ 22,643	12.1%

*Asia Pacific:* The increase in constant currency net sales in Greater China continues to be driven by growth in Mainland China, where local currency net sales increased 18.6%. The increase in net sales in Southeast Asia Pacific was driven by double digit local currency net sales growth in several markets, including Malaysia, New Zealand, Australia, and Indonesia. The increase in constant currency net sales in North Asia continues to be driven by growth in South Korea, where local currency net sales increased 29.4%.

*Americas and Europe:* The decrease in constant currency net sales in this region was driven by local currency decreases in the U.S. and Mexico, which decreased a 4.8% and 7.9%, respectively. Sustainable customer growth remains our top priority for this region as well as each of our other reporting regions.

Table of Contents

*Gross Profit*

Gross profit increased 30 basis points to 83.0% of net sales for the nine months of 2018, from 82.7% in the prior year. This increase can be attributed to favorable changes in currency exchange rates in markets outside of China, leverage from higher sales on fixed costs, and lower relative freight costs, as well as annual price adjustments. With the exception of China, where products are manufactured in-market, changes in currency exchange rates affect the valuation of U.S. manufactured inventory that is transferred to international subsidiaries. Improvement in gross profit margin were partially offset by higher reserves for inventory obsolescence and costs associated with our new Celavive® skincare line, which carries a higher relative cost than other products.

*Associate Incentives*

Associate incentives were 44.1% of net sales for the first nine months of 2018, compared with 45.2% in the prior year. This decrease can be primarily attributed to a higher level of contests, incentive promotions and reward trips during the first nine months of 2017 and sales from our new Celavive® line, which have a lower incentive payout.

*Selling, General and Administrative Expenses*

In absolute terms, our selling, general and administrative expense increased \$13.1 million during the first nine months of 2018 when compared with the same period of the prior year. This increase can be attributed to higher employee related costs in the current year period. This absolute increase was partially offset by the incremental expense related to China and our internal investigation and an impairment charge related to our note receivable from a former third-party supplier in the first nine months of 2017.

*Income Taxes*

Income taxes were 33.9% of earnings in the first nine months of 2018 compared with 30.4% of earnings in the prior year. The higher effective tax rate for the first nine months compared with the same period of the prior-year is primarily due to the recognition of excess tax benefits from equity award exercises recognized during the prior period. Our effective tax rate, on a year-over-year basis, is not (and will not be) comparable during 2018 because of the impact of U.S. tax reform.

*Diluted Earnings Per Share*

Diluted earnings per share increased 38.2% in the first nine months of 2018 when compared with the same period of the prior year. This increase can be attributed to strong growth in net sales and improved operating margins offset, in part, by a higher effective tax rate.

## Liquidity and Capital Resources

We have historically met our working capital and capital expenditure requirements by using both net cash flow from operations and periodically drawing on our line of credit. Our principal source of liquidity is our operating cash flow. Although we are required to maintain cash deposits with banks in certain of our markets, there are currently no material restrictions on our ability to transfer and remit funds among our international markets. In Mainland China, however, our compliance with Chinese accounting and tax regulations promulgated by the State Administration of Foreign Exchange (SAFE) results in transfer and remittance of our profits and dividends from Mainland China to the United States on a delayed basis. If SAFE or other Chinese regulators introduce new regulations, or change existing regulations which allow foreign investors to remit profits and dividends earned in China to other countries, our ability to remit profits or pay dividends from Mainland China may be limited in the future.

We have historically generated positive cash flow due to our strong operating margins. Net cash flow from operating activities totaled \$111.7 million in the first nine months of 2018. Items increasing cash flows from operations in the first nine months of 2018 include: (i) net earnings, and (ii) non-cash items. These increases were partially offset by (i) cash used on inventories primarily attributed to our new Celavive® line, and (ii) tax payments.

Net cash flow from operating activities totaled \$68.6 million in the first nine months of 2017. Items increasing cash flows from operations in the first nine months of 2017 include: (i) net earnings, and (ii) non-cash items. These increases were reduced by (i) payment of accrued employee compensation costs, (ii) payment of accrued commissions, and (iii) deferred revenue.

Table of Contents

Cash and cash equivalents and securities held-to-maturity increased to \$321.4 million at September 29, 2018, from \$247.1 million at December 30, 2017. Of the \$321.4 million of cash and cash equivalents and securities held-to-maturity held at September 29, 2018, \$63.2 million was held as cash and cash equivalents and \$81.7 million as securities held-to-maturity in the United States. Of the remaining \$176.5 million held by our international subsidiaries, \$132.3 million was concentrated in China. Cash and cash equivalents held at December 30, 2017, totaled \$247.1 million of which, \$52.2 million was held in the United States. Of the remaining \$194.9 million held by our international subsidiaries, \$142.3 million was held in China. Net working capital increased to \$281.9 million at September 29, 2018, from \$199.0 million at December 30, 2017.

*Line of Credit*

Information with respect to our line of credit may be found in Note H to the Condensed Consolidated Financial Statements included in Item 1 of Part I of this Report on Form 10-Q.

*Share Repurchase*

During the nine months ended September 29, 2018, we repurchased 217,000 shares of our common stock for \$25.6 million under our share repurchase plan, at an average market price of \$117.88. At September 29, 2018, the remaining approved repurchase amount under the plan was \$24.4 million. There currently is no expiration date on the remaining approved repurchase amount and no requirement for future share repurchases.

On October 23, 2018, our Board of Directors authorized an increase in the amount available under the share repurchase plan to a total of \$150.0 million. The authorization is inclusive of the \$24.4 million that was remaining under the prior authorization at September 29, 2018. Subsequent to September 29, 2018, and through November 2, 2018, we repurchased and retired 235,000 shares of common stock for \$26.7 million, at an average market price of \$113.57 per share.

*Off-Balance Sheet Arrangements*

None.

*Summary*

We believe that current cash balances, investments, future cash provided by operations, and amounts available under our line of credit will be sufficient to cover our operating and capital needs in the ordinary course of business for the foreseeable future. If we experience an adverse operating environment or unanticipated and unusual capital expenditure requirements, additional financing may be required. No assurance can be given, however, that additional financing, if required, would be available at all or on favorable terms. We might also require or seek additional financing for the purpose of expanding into new markets, growing our existing markets, or for other reasons. Such financing may

include the use of additional debt or the sale of additional equity securities. Any financing which involves the sale of equity securities or instruments that are convertible into equity securities could result in immediate and possibly significant dilution to our existing shareholders.

**Cautionary Note Regarding Forward-Looking Statements and Certain Risks**

The statements contained in this report that are not purely historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Exchange Act. These statements represent our expectations, hopes, beliefs, anticipations, commitments, intentions, and strategies regarding the future. They may be identified by the use of words or phrases such as believes, expects, anticipates, should, plans, estimates, and potential, among others. Forward-looking statements include, but are not limited to, statements contained in Management's Discussion and Analysis of Financial Condition and Results of Operations regarding our financial performance, revenue, and expense levels in the future and the sufficiency of our existing assets to fund our future operations and capital spending needs. Readers are cautioned that actual results could differ materially from the anticipated results or other expectations that are expressed in these forward-looking statements for the reasons that are detailed in our most recent Annual Report on Form 10-K. The fact that some of these risk factors may be the same or similar to those in our past SEC reports means only that the risks are present in multiple periods. We believe that many of the risks detailed here and in our other SEC filings are part of doing business in the industry in which we operate and will likely be present in all periods reported. The fact that certain risks are common in the industry does not lessen their significance. The

Table of Contents

forward-looking statements contained in this report are made as of the date of this report, and we assume no obligation to update them or to update the reasons why our actual results could differ from those that we have projected. Among others, risks and uncertainties that may affect our business, financial condition, performance, development, and results of operations include:

- Our ability to attract and maintain a sufficient number of Associates and Preferred Customers;
  
- Our dependence upon a network marketing system to distribute our products and the activities of our independent Associates;
  
- The expansion of our business in China through BabyCare;
  
- Unanticipated effects of changes to our Compensation Plan;
  
- Our planned expansion into international markets, including delays in commencement of sales or product offerings in any new market, delays in compliance with local marketing or other regulatory requirements, or changes in target markets;
  
- General economic conditions, both domestically and internationally;
  
- The impact of changes in trade policies and tariffs;
  
- Potential political events, natural disasters, or other events that may negatively affect economic conditions;
  
- Potential effects of adverse publicity regarding USANA, nutritional supplements, or the network marketing industry;
  
- Reliance on key management personnel;

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

- Extensive government regulation of our products, manufacturing, and network marketing system;
- Potential inability to sustain or manage growth, including the failure to continue to develop new products;
- An increase in the amount of Associate incentives;
- Our reliance on the use of information technology;
- Disruption in operations or liability resulting from cybersecurity, data breaches or failure to comply with data privacy and/or data security laws and regulations;
- The effects of competition from new and established network and direct selling organizations in our key markets;
- The adverse effect of the loss of a high-level sponsoring Associate, together with a group of leading Associates, in that person's downline;
- The loss of product market share or Associates to competitors;
- Potential adverse effects of customs, duties, taxation, and transfer pricing regulations, including regulations governing distinctions between and our responsibilities to employees and independent contractors;
- The fluctuation in the value of foreign currencies against the U.S. dollar;
- Our reliance on outside suppliers for raw materials and certain manufactured items;
- Shortages of raw materials that we use in certain of our products;
- Significant price increases of our key raw materials;

- Product liability claims and other risks that may arise with our manufacturing activity;
- Intellectual property risks;
- Liability claims that may arise with our Athlete Guarantee program;
- Continued compliance with debt covenants;
- Disruptions to shipping channels that are used to distribute our products to international warehouses;
- The introduction of new laws or changes to existing laws, both domestically and internationally; and
- The outcome of the internal investigation into our China operations, as well as other regulatory and litigation matters.

Table of Contents

**Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

There have been no material changes from the information presented for the year ended December 30, 2017.

**Item 4. CONTROLS AND PROCEDURES**

**Disclosure Controls and Procedures**

We maintain disclosure controls and procedures that are designed to ensure that information that is required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods that are specified in the SEC's rules and forms and that such information is accumulated and communicated to management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding any required disclosure. In designing and evaluating these disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

As of the end of the period covered by this report, our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial and Accounting Officer) evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 29, 2018.

**Changes in Internal Control Over Financial Reporting**

There were no changes in our internal control over financial reporting during the fiscal quarter ended September 29, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II. OTHER INFORMATION**

**Item 1. Legal Proceedings**

We are a party to litigation and other proceedings that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters.

Information with respect to our legal proceedings may be found in Note I to the Condensed Consolidated Financial Statements included in Item 1 Part I of this Report on Form 10-Q.

**Item 1A. Risk Factors**

Our business, results of operations, and financial condition are subject to various risks. These risks are described elsewhere in this Quarterly Report on Form 10-Q and our other filings with the SEC, including the 2017 Form 10-K and the additional risk factors disclosed in our Form 10-Q for the quarter-ended June 30, 2018. The risk factors identified in our 2017 Form 10-K and Form 10-Q for the quarter-ended June 30, 2018 have not changed in any material respect.

Table of Contents**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds****Issuer Purchases of Equity Securities**

(amounts in thousands, except per share data)

Fiscal July (Jul. 1, 2018 through Aug. 4, 2018)	0	\$	0.00	0	\$ 47,057
Fiscal August (Aug 5, 2018 through Sep. 1, 2018)	0	\$	0.00	0	\$ 47,057
Fiscal September (Sep. 2, 2018 through Sep. 29, 2018)	178	\$	127.43	0	\$ 24,410

\* Our share repurchase plan has been ongoing since the fourth quarter of 2000, with the Board of Directors periodically approving additional dollar amounts for share repurchases under the plan. Our share repurchases may occur through open market purchases or pursuant to a Rule 10b5-1 trading plan. There is no requirement for future share repurchases, and there currently is no expiration date on the approved repurchase amount.

**Item 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**Item 4. MINE SAFETY DISCLOSURES**

None.

**Item 5. OTHER INFORMATION**

None.

**Item 6. EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
31.1	<u>Certification of Principal Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)</u>
31.2	<u>Certification of Principal Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)</u>
32.1	<u>Certification of Principal Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 (filed herewith)</u>
32.2	<u>Certification of Principal Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 (filed herewith)</u>
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 7, 2018

USANA HEALTH SCIENCES, INC.

/s/ G. Douglas Hekking  
G. Douglas Hekking  
Chief Financial Officer  
(Principal Financial Officer)